Bind Benefits, a personalized health plan that creates an intuitive fit between people’s health benefit and the way they actually use health care, was named to the CB Insights Digital Health 150 list — the 150 most promising private digital health companies in the world.
“The health benefits cost curve is unsustainable. And it’s not okay. Employers need better solutions to offer an affordable, attractive health benefit. And employees deserve a benefit they understand and one that helps them make informed decisions,” said Bind CEO Tony Miller. “Bind is disrupting the status quo through smarter design of health insurance. By allowing members to see treatment options and compare costs before making a decision, we help people buy better. The growth and momentum we’re experiencing speaks to the value we’re delivering for both employers and employees—and being named to the Digital Health 150 list underscores that. I’m proud of the talented and hard-working Bind team that is united around the common purpose of making health insurance personal.”
CB Insights selects the Digital Health 150 from hundreds of applicants through an evidence-based approach and based on factors, such as: patent activity, investor quality, news sentiment analysis, market potential, partnerships, competitive landscape, team strength and tech novelty. CB Insights also uses a proprietary algorithm to measure the overall health and growth potential of private companies to help predict a company’s momentum. Click here to read more.
Reify Health, a health tech company that markets cloud computing systems for the biopharma industry, has raised $30 million in a Series B funding round. The company’s software seeks to upgrade the computer systems that healthcare staff at clinical trial sites use to run studies in order to accelerate enrollment and reduce workloads. Battery Ventures led the round, with participation from Sierra Ventures and Asset Management Ventures. Click here to read more.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Bodyport, a cardiology startup, raised $11.2 million as part of a Series A round. Boehringer Ingelheim Venture Fund led the round, joined by existing investors Playground Global and Initialized Capital, among others. The investment is aimed at helping the company deepen important health partnerships and support the launch of a virtual cardiac clinic. Click here to read more.
MedCity’s next conference, INVEST Digital Health virtual, is set for September 21-25. It will spotlight healthcare startups as part of the Pitch Perfect competition across four categories: Chronic Disease Management and Value-based Care Technology to Boost Payer/Provider Efficiency, Home Health, and Employee Benefits. The new deadline for applications is Friday, August 21, 5pm E.T. To learn more and apply, click here.
Picture: akindo, Getty Images
